Keeping Pace in Women’s Cancers: Updates in Triple-Negative Breast Cancer

Keeping Pace in Women’s Cancers: Updates in Triple-Negative Breast Cancer

Keeping Pace in Women’s Cancers: Updates in Triple-Negative Breast Cancer

Metastatic TNBC presents a complex clinical challenge to physicians. How will emerging immunotherapies shift the treatment paradigm for TNBC?

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Our understanding of the biology of triple-negative breast cancer (TNBC) is leading to the development of more targeted therapies. Dr. Peter Schmid and Dr. Javier Cortés discuss the role of immunotherapies in the treatment of metastatic TNBC and how to determine if your patient is eligible for combination immunotherapies.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Javier Cortés, MD, PhD
    Head, Breast Cancer Program
    IOB Institute of Oncology
    Madrid & Barcelona, Spain 

    Consulting Fees: Merck
    Contracted Research: Merck Sharp&Dohme

    Professor Peter Schmid, FRCP, MD, PhD
    Chair, Cancer Medicine
    Barts Cancer Institute
    Queen Mary University of London
    London, England

    Consulting Fees: Merck

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough MD, FAAFP has nothing to disclose.
    • Tricia O’Leary has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe barriers to the optimal treatment of TNBC and how such barriers may be effectively addressed to ensure accurate and timely diagnosis and management.
    • Assess advances in the understanding of TNBC biology and how these advances assist clinicians in determining treatment of TNBC.
    • Assess the safety and efficacy of new and emerging therapies (eg, immunotherapies) in the treatment of TNBC.
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, and clinicians treating breast cancer.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    ReachMD Healthcare Image

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions.  Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free